U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H27NO4.ClH
Molecular Weight 369.883
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Nolomirole hydrochloride

SMILES

Cl.CNC1CCC2=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=CC=C2C1

InChI

InChIKey=TWTMQRXNAZGSCE-UHFFFAOYSA-N
InChI=1S/C19H27NO4.ClH/c1-11(2)18(21)23-16-9-6-13-10-14(20-5)7-8-15(13)17(16)24-19(22)12(3)4;/h6,9,11-12,14,20H,7-8,10H2,1-5H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H27NO4
Molecular Weight 333.422
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Nolomirole (CHF1035) is an orally active, selective dopamine agonist, primarily activating DA2- and alpha2 receptors, thereby inhibiting norepinephrine release, which may be beneficial in heart failure. Nolomirole is able to attenuate the heart failure signs in the monocrotaline-induced congestive heart failure. CHF1035 is a mixture of two enantiomers, CHF1800 (+) and CHF1810 (-). CHF1035 and its metabolite CHF1024 significantly decreased the IOP in rabbits, and are potential novel IOP lowering agents. Especially, CHF1035 produced a substantial decrease in IOP for a prolonged period of time, and thus may prove useful in glaucoma therapy. Nolomirole is a pre-synaptic stimulator of DA2-dopaminergic and α2-adrenergic receptors in peripheral sympathetic nerve endings. These receptors act as a negative feedback mechanism, inhibiting norepinephrine secretion. In early phase clinical studies lasting 1–3 months, nolomirole reduced peripheral systemic resistance and 24 hour blood pressure and increased cardiac output. In a study of 29 patients with heart failure, followed for 10 days, a reduction in plasma norepinephrine was demonstrated. In spite of the fact that Nolomirole was in clinical trials for the treatment of heart failure, its development was discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Polymorphism of rac-5,6-diisobutyryloxy-2-methylamino-1,2,3,4-tetrahydro-naphthalene hydrochloride (CHF 1035). I. Thermal, spectroscopic, and X-ray diffraction properties.
2001 Aug
A novel D2-dopaminergic and alpha2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits.
2003 Jun
Effect of nolomirole on monocrotaline-induced heart failure.
2004 Jan
Patents

Sample Use Guides

5 mg b.i.d. of nolomirole in patients with severe left ventricular systolic dysfunction, recently in New York Heart Association (NYHA) class III/IV. A dose of 5 mg b.i.d. of nolomirole was not beneficial (or harmful) in patients with heart failure.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:53:17 GMT 2023
Edited
by admin
on Sat Dec 16 08:53:17 GMT 2023
Record UNII
KX9X4DN6YV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Nolomirole hydrochloride
Common Name English
Propanoic acid, 2-methyl-, 1,1′-[5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl] ester, hydrochloride (1:1)
Common Name English
CHF1035
Code English
CHF-1035
Code English
Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (±)-
Common Name English
Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride
Common Name English
Code System Code Type Description
CAS
138531-51-8
Created by admin on Sat Dec 16 08:53:17 GMT 2023 , Edited by admin on Sat Dec 16 08:53:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID70930143
Created by admin on Sat Dec 16 08:53:17 GMT 2023 , Edited by admin on Sat Dec 16 08:53:17 GMT 2023
PRIMARY
FDA UNII
KX9X4DN6YV
Created by admin on Sat Dec 16 08:53:17 GMT 2023 , Edited by admin on Sat Dec 16 08:53:17 GMT 2023
PRIMARY
PUBCHEM
219049
Created by admin on Sat Dec 16 08:53:17 GMT 2023 , Edited by admin on Sat Dec 16 08:53:17 GMT 2023
PRIMARY